Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

B-cell Lymphoma

All Drugs and Chemicals

Antineoplastic Agents

Immunomodulating Agents

Nivolumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Nivolumab followed by Urelumab

Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles

Urelumab

Bristol-Myers Squibb

The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma

The total number of subjects whose best overall response (BOR) is either a complete response or partial response for solid tumors and complete remission or partial remission for B-cell NHL, divided by the total number of subjects in the population of interest.

Objective response rate (ORR) is defined as the total number of subjects whose BOR is either CR or PR divided by the total number of subjects in the population of interest.

DOR is defined as the number of days between the date of first response and the subsequent date of objectively documented disease progression based on the criteria (RECIST v1.1) or relapse based on IWG, or death due to any cause, if death occurred within 100 days after last dose, whichever occurs first.

Data was not collected due to discontinuation of the study/Due to study termination.

PFSR is defined as the probability of a subject remaining progression-free and surviving a specific length of time.

Data was not collected due to discontinuation of the study/Due to study termination.

Data was not collected due to discontinuation of the study/Due to study termination.

TRT A

TRT B

TRT D

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Bristol-Myers Squibb Study Director

The Incidence of Adverse Events.

The Incidence of Seriuos Adverse Events.

The Incidence of Death.

Complete response

Partial response

URE8 Q4WK+NIV240mg Q2WK- Non small cell lung cancer pd1/pd-l1 experienced

TRT D - NSCLC pd1/Pd-l1 Experienced

URE8 Q4WK+NIV240mg Q2WK - Non samll cell lung cancer pd1/pd-l1 naive.

TRT D - NSCLC pd1/Pd-l1 Naive

URE8 Q4WK+NIV240mg Q2WK - Melanoma pd1/pd-l1 experienced

TRT D - Melanoma pd1/Pd-l1 Experienced

URE3 Q4WK+NIV3 Q2WK - Melanoma pd1/pd-l1 naive

TRT A - Melanoma pd1/Pd-l1 Naive

URE8 Q4WK+NIV3 Q2WK - Melanoma pd1/pd-l1 naive

TRT B -

URE8 Q4WK+NIV240mg Q2WK - Melanoma pd1/pd-l1 naive

TRT D - Melanoma pd1/Pd-l1 Naive

URE3 Q4WK+NIV3 Q2WK - Squamous cell carcinoma of head and neck.

TRT A - SCCHN

URE8 Q4WK+NIV240mg Q2WK - Squamous cell carcinoma of head and neck.

TRT D - SCCHN

TRT A - Other Solid Tumors

URE8 Q4WK+NIV3 Q2WK - Other Solid tumors.

TRT B - Other Solid Tumors

URE8 Q4WK+NIV240mg Q2WK - Diffuse Large B-cell lymphoma.

TRT D - DLBCL

URE8 Q4WK+NIV240mg Q2WK - Follicular Lymphoma.

Spots Global Cancer Trial Database for An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial